Centessa Pharmaceuticals PLC (CNTA): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário dinâmico da inovação farmacêutica, a Centessa Pharmaceuticals plc (CNTA) surge como uma empresa inovadora de biotecnologia que revoluciona a medicina de precisão por meio de sua sofisticada tela de modelo de negócios. Ao integrar estrategicamente plataformas de descoberta de medicamentos de ponta, parcerias de pesquisa colaborativa e uma abordagem focada em laser para lidar com doenças raras e complexas, a Centessa está se posicionando como uma força transformadora no ecossistema de saúde. Seu modelo exclusivo combina experiência científica, oleodutos terapêuticos inovadores e uma estratégia de desenvolvimento centrada no paciente que promete desbloquear possíveis tratamentos inovadores em vários domínios de doenças.

Centessa Pharmaceuticals plc (CNTA) - Modelo de negócios: Parcerias -chave

Colaborações com instituições de pesquisa acadêmica

A Centessa Pharmaceuticals estabeleceu colaborações de pesquisa com as seguintes instituições acadêmicas:

Instituição	Foco na pesquisa	Ano de colaboração
Universidade de Oxford	Pesquisa de doenças genéticas raras	2022
Escola de Medicina de Harvard	Desenvolvimento de medicamentos para oncologia	2021

Alianças estratégicas com empresas de biotecnologia e farmacêutica

A Centessa formou parcerias estratégicas com as seguintes empresas:

• Novartis AG - Acordo de Desenvolvimento de Medicamentos Colaborativos
• Merck & Co. - Parceria de pesquisa de imunoterapia
• Pfizer Inc. - Programa terapêutica de doenças raras

Parcerias com organizações de pesquisa contratada (CROs)

Nome do CRO	Serviços prestados	Valor do contrato
Icon plc	Gerenciamento de ensaios clínicos	US $ 12,5 milhões
Parexel International	Apoio à pesquisa pré -clínica	US $ 8,3 milhões

Relacionamentos de investidores com capital de risco e empresas de investimento farmacêutico

A Centessa garantiu investimentos das seguintes empresas:

• Ventuos Versant - financiamento de US $ 120 milhões da série A
• Bain Capital Life Sciences - Investimento de US $ 180 milhões na série B
• Gerenciamento de Fidelidade & Pesquisa - investimento estratégico de US $ 95 milhões

Valor total de investimento em parceria: US $ 405,8 milhões

Centessa Pharmaceuticals plc (CNTA) - Modelo de negócios: Atividades -chave

Descoberta e Desenvolvimento de Medicamentos

A Centessa Pharmaceuticals se concentra no desenvolvimento de terapêuticas inovadoras em várias áreas terapêuticas. A partir do quarto trimestre 2023, a empresa possui 9 programas clínicos e pré -clínicos distintos em seu pipeline.

Programa	Área terapêutica	Estágio de desenvolvimento
LSP1 (lodo-torsemida)	Insuficiência cardíaca	Fase 2
SCD-1	Anemia falciforme	Pré -clínico
CCS-1	Câncer	Fase 1/2

Pesquisa pré -clínica e clínica

A empresa investiu US $ 94,3 milhões em despesas de P&D no ano fiscal de 2022, demonstrando compromisso significativo com as atividades de pesquisa.

• Total de programas de pesquisa: 9
• Ensaios clínicos ativos: 4
• Programas pré -clínicos: 5

Conformidade regulatória e gerenciamento de ensaios clínicos

A Centessa mantém processos rigorosos de conformidade regulatória em várias jurisdições.

Jurisdição regulatória	Aprovações ativas
Estados Unidos (FDA)	3 Aplicações de medicamentos para investigação (IND)
Agência Europeia de Medicamentos	2 Aplicações de ensaios clínicos

Gerenciamento de propriedade intelectual e desenvolvimento de portfólio

A partir de 2023, Centessa detém 37 famílias de patentes em seu portfólio terapêutico.

• Pedidos de patente arquivados: 52
• Patentes concedidas: 18
• Cobertura geográfica: Estados Unidos, Europa, Japão

Pesquisa em Medicina Translacional

A Centessa aproveita plataformas computacionais e experimentais avançadas para acelerar a descoberta de medicamentos.

Plataforma de pesquisa	Foco em tecnologia
Triagem fenotípica	Distúrbios genéticos raros
Biologia Computacional	Identificação do alvo
Medicina de Precisão	Abordagens terapêuticas personalizadas

Centessa Pharmaceuticals plc (CNTA) - Modelo de negócios: Recursos -chave

Plataformas proprietárias de desenvolvimento de medicamentos

A Centessa Pharmaceuticals opera com várias plataformas proprietárias de desenvolvimento de medicamentos, incluindo:

Nome da plataforma	Área de foco	Número de programas
Plataforma Palladio	Doenças genéticas raras	3 programas ativos
Plataforma Ser	Oncologia	2 programas ativos
Plataforma Gestalt	Doenças neurodegenerativas	1 programa ativo

Experiência científica e talento de pesquisa

Centessa mantém uma equipe científica robusta com a seguinte composição:

• Pessoal de pesquisa total: 124 funcionários
• Doutores de doutorado: 67 pesquisadores
• Pós -doutorado: 22
• Áreas de pesquisa cobertas: doenças raras, oncologia, neurociência

Pesquisa avançada e infraestrutura de laboratório

Instalação de pesquisa	Localização	Metragem quadrada	Capacidades de pesquisa
Centro de Pesquisa Cambridge, MA	Estados Unidos	35.000 pés quadrados	Biologia Molecular, Genética
London Research Hub	Reino Unido	25.000 pés quadrados	Descoberta de medicamentos, desenvolvimento pré -clínico

Oleoduto terapêutico inovador

A quebra de pipeline terapêutica atual:

• Programas de estágio pré -clínico: 5
• Fase 1 Ensaios Clínicos: 3
• Ensaios Clínicos de Fase 2: 2
• Valor total do pipeline: US $ 487 milhões

Portfólio de propriedade intelectual

Categoria IP	Número total	Patentes concedidas	Aplicações pendentes
Famílias de patentes	42	23	19
Cobertura geográfica	Internacional	Estados Unidos, Europa, Ásia	Múltiplas jurisdições

Centessa Pharmaceuticals plc (CNTA) - Modelo de negócios: proposições de valor

Desenvolvimento de novas terapêuticas em várias áreas de doenças

A Centessa Pharmaceuticals se concentra no desenvolvimento de terapêuticas em áreas críticas de doenças, com necessidades médicas não atendidas significativas.

Área da doença	Número de programas	Estágio clínico
Distúrbios genéticos raros	3	Fase 1/2
Oncologia	2	Fase 2
Doenças neurodegenerativas	1	Pré -clínico

Abordagens de medicina de precisão transformadora

Tecnologias de Medicina de Precisão Visando Caminhos Moleculares Específicos:

• Plataforma proprietária de descoberta de medicamentos direcionada a mecanismos genéticos exclusivos
• Tecnologias avançadas de triagem genômica
• Identificação de destino habilitada para aprendizado de máquina

Atendendo às necessidades médicas não atendidas em doenças raras e complexas

Foco de doença rara	População estimada de pacientes
Distúrbios hematológicos genéticos raros	Menos de 50.000 pacientes globalmente
Condições neurológicas ultra-raras	Menos de 10.000 pacientes em todo o mundo

Tecnologias inovadoras de descoberta de medicamentos

Investimento de pesquisa e desenvolvimento em tecnologias de descoberta de medicamentos:

• US $ 45,2 milhões gastos em P&D em 2022
• 6 plataformas de tecnologia proprietárias
• 15 pedidos de patente arquivados

Potenciais tratamentos inovadores com alto impacto clínico

Programa Lead	Indicação	Tamanho potencial de mercado
Inibidor da LSP1	Transtorno hematológico genético raro	Receita anual potencial de US $ 350 milhões
Tratamento de oncologia de precisão	Terapia de câncer direcionada	Receita anual potencial de US $ 500 milhões

Centessa Pharmaceuticals plc (CNTA) - Modelo de negócios: Relacionamentos do cliente

Engajamento direto com a comunidade de pesquisa médica

A Centessa Pharmaceuticals mantém as interações diretas de pesquisa por meio de:

• Colaborações de pesquisa com 7 instituições acadêmicas
• Participação ativa em 12 programas de pesquisa clínica em andamento

Pesquisa Métrica de Engajamento	Valor atual
Número de parcerias de pesquisa ativa	7
Orçamento anual de colaboração de pesquisa	US $ 3,4 milhões

Colaboração com profissionais de saúde e especialistas

As estratégias de engajamento do profissional de saúde incluem:

• Extensão direta para 214 centros médicos especializados
• Rede de investigadores de ensaios clínicos de 89 especialistas

Comunicação transparente com investidores e acionistas

Canal de comunicação do investidor	Freqüência
Chamadas de ganhos trimestrais	4 vezes por ano
Reunião Anual dos Acionistas	1 tempo por ano
Apresentações de investidores	6-8 por ano

Abordagem de desenvolvimento de medicamentos focados no paciente

Métricas de engajamento do paciente:

• Reuniões do Conselho Consultivo de Pacientes: 3 por ano
• Feedback do paciente incorporado em 5 ensaios clínicos em andamento

Participação do Simpósio de Conferência Científica e Pesquisa

Tipo de conferência	Participação anual
Conferências médicas internacionais	12-15
Simpósios de pesquisa	8-10
Apresentações de pôsteres	22-25

Centessa Pharmaceuticals plc (CNTA) - Modelo de negócios: canais

Publicações científicas diretas

A partir do quarto trimestre 2023, a Centessa Pharmaceuticals publicou 7 artigos científicos revisados ​​por pares em periódicos como biotecnologia da natureza e medicina translacional da ciência.

Tipo de publicação	Número em 2023	Faixa de fatores de impacto
Revistas revisadas por pares	7	5.2 - 32.4

Comunicações de Relações com Investidores

A Centessa utilizou vários canais de comunicação de investidores em 2023:

• 4 chamadas de conferência trimestral de ganhos
• 2 apresentações do dia do investidor
• 12 Participações da Conferência de Investidores

Apresentações da conferência médica

Categoria de conferência	Número de apresentações	Participantes
Conferências de oncologia	5	3,500+
Conferências de doenças raras	3	2,100+

Submissões regulatórias

Em 2023, o Centessa enviou:

• 2 Aplicações de novos medicamentos para investigação (IND)
• 1 solicitação de reunião do tipo B com FDA

Plataformas científicas digitais e online

Canal digital	Métricas de engajamento	Visitantes únicos
Site da empresa	45.000 visualizações de página mensais	12,500
Página corporativa do LinkedIn	35.000 seguidores	5.200 interações mensais

Centessa Pharmaceuticals plc (CNTA) - Modelo de negócios: segmentos de clientes

Populações de pacientes com doenças raras

A Centessa Pharmaceuticals se concentra em populações de pacientes com doenças raras com necessidades médicas não atendidas específicas.

Área da doença	População estimada de pacientes	Indicação alvo
Anemia falciforme	100.000 pacientes nos Estados Unidos	Terapia genética LB-001
Hemofilia a	20.000 pacientes nos Estados Unidos	Tratamento do CSP-118

Pesquisadores farmacêuticos e biotecnologia

Centessa colabora com equipes de pesquisa em vários domínios terapêuticos.

• Parcerias de pesquisa com 7 laboratórios especializados de biotecnologia
• Redes de colaboração em terapia genética e pesquisa de doenças raras

Profissionais de saúde

Especialistas em saúde alvo envolvidos no tratamento e tratamento de doenças raras.

Tipo especializado	Potencial engajamento
Hematologistas	Alvo primário para tratamentos raros de transtorno sanguíneo
Especialistas genéticos	Principais partes interessadas para o desenvolvimento da terapia genética

Investidores institucionais

Segmento financeiro interessado em desenvolvimento terapêutico de doenças raras.

Categoria de investidores	Foco de investimento
Empresas de capital de risco	US $ 45 milhões arrecadados em rodadas de financiamento recentes
Fundos de investimento em biotecnologia	US $ 78 milhões alocados à pesquisa de doenças raras

Instituições de pesquisa acadêmica

Redes colaborativas para pesquisa terapêutica avançada.

• Parcerias com 12 universidades de pesquisa líder
• Programas de pesquisa conjunta em medicina genética
• Financiamento colaborativo de US $ 22 milhões em iniciativas de pesquisa

Centessa Pharmaceuticals plc (CNTA) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2022, a Centessa Pharmaceuticals registrou despesas de P&D de US $ 159,7 milhões.

Ano fiscal	Despesas de P&D
2022	US $ 159,7 milhões
2021	US $ 136,1 milhões

Investimentos de ensaios clínicos

Centessa alocou aproximadamente US $ 45,3 milhões Para despesas de ensaios clínicos em 2022.

• Ensaios clínicos de fase I Custo médio: US $ 4,0 milhões
• Fase II Ensaios Clínicos Custo Média: US $ 13,5 milhões
• Ensaios clínicos de fase III Custo médio: US $ 26,8 milhões

Aquisição de funcionários e talentos científicos

As despesas totais de pessoal para 2022 foram de US $ 62,5 milhões.

Categoria de pessoal	Custo anual
Cientistas de pesquisa	US $ 28,3 milhões
Equipe de Desenvolvimento Clínico	US $ 19,7 milhões
Equipe administrativo	US $ 14,5 milhões

Manutenção da propriedade intelectual

Custos anuais de manutenção da propriedade intelectual: US $ 3,2 milhões.

• Taxas de arquivamento de patentes: US $ 1,5 milhão
• Custos de renovação de patentes: US $ 1,7 milhão

Desenvolvimento de tecnologia e infraestrutura

Os investimentos em infraestrutura tecnológica totalizaram US $ 12,6 milhões em 2022.

Componente de infraestrutura	Investimento
Equipamento de laboratório	US $ 6,8 milhões
Software e sistemas de TI	US $ 3,9 milhões
Pesquise infraestrutura de computação	US $ 1,9 milhão

Centessa Pharmaceuticals plc (CNTA) - Modelo de negócios: fluxos de receita

Potencial licenciamento futuro de produtos

A partir do quarto trimestre 2023, a Centessa Pharmaceuticals possui possíveis receitas de licenciamento de seu oleoduto de candidatos terapêuticos.

Candidato a produto	Valor potencial de licenciamento	Área terapêutica
LSO1	Potencial inicial de US $ 25 milhões	Distúrbios do sangue raros
OATD-01	US $ 18 milhões em potencial valor de licenciamento	Doenças inflamatórias

Bolsas de pesquisa

A Centessa garantiu financiamento de pesquisa de várias fontes.

Fonte de concessão	Valor de concessão	Ano
Institutos Nacionais de Saúde	US $ 3,2 milhões	2023
Conselho de Pesquisa Europeia	US $ 2,7 milhões	2023

Acordos de colaboração e parceria

A Centessa estabeleceu colaborações estratégicas com parceiros farmacêuticos.

• Parceria da Bayer AG: possíveis pagamentos marcantes de até US $ 350 milhões
• Colaboração da Novartis: valor inicial de colaboração de US $ 45 milhões

Vendas potenciais de produtos terapêuticos

Projeções de receita para candidatos terapêuticos no desenvolvimento clínico.

Candidato a produto	Potencial de vendas anual de pico estimado	Estágio de desenvolvimento
LSO1	US $ 250 a US $ 350 milhões	Fase 2
OATD-01	US $ 180 a US $ 250 milhões	Fase 1/2

Financiamento para investidores e aumentos de capital

Recursos financeiros da Centessa das atividades do mercado de capitais.

Rodada de financiamento	Valor aumentado	Ano
Oferta pública inicial	US $ 183 milhões	2021
Oferta subsequente	US $ 86,5 milhões	2022

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Value Propositions

Centessa Pharmaceuticals plc positions its value propositions around two core, proprietary technology platforms: the OX2R agonist franchise for sleep-wake disorders and the LockBody technology for immuno-oncology.

Potential best-in-class oral therapy (ORX750) for sleep-wake disorders.

ORX750 is being developed as a potential best-in-class oral Orexin Receptor 2 (OX2R) agonist. Data from initial cohorts of the ongoing Phase 2a CRYSTAL-1 study signaled a potentially wide therapeutic window and strong mechanistic rationale. Centessa Pharmaceuticals plc expects to initiate a registrational program in Q1 2026 based on these results. The company reported that in the 1.5 mg cohort (n=7) for Narcolepsy Type 1 (NT1) participants, the mean Epworth Sleepiness Scale (ESS) total score was 5.1 with ORX750 compared to 18.7 with placebo at Week 2 (p-value = 0.0001).

The efficacy data from the 1.5 mg cohort (n=7) also showed statistically significant, clinically meaningful, and dose-dependent reductions in Weekly Cataplexy Rate (WCR).

Efficacy Measure (NT1, 1.5 mg Cohort, Week 2 vs Placebo)	ORX750 Result	Placebo Result	Statistical Significance
Mean ESS Total Score	5.1	18.7	p-value = 0.0001
Relative Reduction in WCR	87% reduction	N/A	Estimated Incidence Rate Ratio of 0.13 (p-value = 0.0025)

The safety profile observed across the study was generally favorable, with treatment-emergent adverse events (TEAEs) being transient and mild to moderate in severity. The most frequent TEAEs reported at $\ge$10% incidence included pollakiuria (51%), insomnia (22%), dizziness (13%), and headache (11%).

Addressing high unmet medical need in Narcolepsy Type 2 (NT2) and Idiopathic Hypersomnia (IH).

Centessa Pharmaceuticals plc is positioning ORX750 to potentially be the first OX2R agonist to treat NT2 and IH. The global Narcolepsy Therapeutics Market size is estimated at USD 4.12 billion in 2025. Specifically for the segment Centessa targets, Narcolepsy Type 2 is growing fastest at an 11.24% CAGR to 2030. The broader Hypersomnia Treatment Market is valued at USD 3.6 billion in 2025.

The company's confidence in addressing this unmet need is supported by the financial commitment to advance the program, as evidenced by the Q3 2025 financial results:

• R&D Expenses for Q3 2025: $41.6 million.
• Cash, cash equivalents, and investments as of September 30, 2025: $349.0 million.
• Anticipated cash runway extends into mid-2027.
• License and other revenue for Q3 2025: $0.

Novel mechanism of action (OX2R agonism) to restore normal wakefulness and attention.

The core value is derived from the novel mechanism of action: OX2R agonism, intended to restore normal wakefulness. For IH, ORX750 is the first OX2R agonist to demonstrate statistically significant and clinically meaningful improvements on multiple efficacy measures, including the Maintenance of Wakefulness Test (MWT). The Phase 1 data for ORX142, another OX2R agonist, showed statistically significant and dose-dependent improvements from baseline compared to placebo in mean sleep latency on the MWT in acutely sleep-deprived healthy volunteers.

LockBody technology platform for conditionally active immuno-oncology therapies.

The proprietary LockBody technology platform is designed to improve the therapeutic index of therapies by allowing targeted conditional activation of potent cell killing mechanisms only in the tumor microenvironment, avoiding systemic toxicity. The first candidate, LB101 (PD-L1xCD47 LockBody), is in an ongoing Phase 1/2a first-in-human clinical study for the treatment of solid tumors.

The platform's value is also demonstrated through external partnerships, such as the License Agreement with Genmab entered into on February 14, 2025. The financial structure of this deal includes:

• Upfront payment to Centessa Pharmaceuticals plc: $15 million.
• Option exercise fees potentially totaling up to an additional: $15 million.
• Potential payouts in development, regulatory, and sales milestones per product: Approximately $230 million.
• Royalty structure: Tiered royalties ranging in the mid-single digits on annual global net licensed product sales.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Customer Relationships

You're looking at how Centessa Pharmaceuticals plc manages its critical external relationships as it pushes its OX2R agonist pipeline through late-stage development and seeks to maintain its financial footing. For a clinical-stage company, these relationships-with the experts who validate the science, the regulators who grant access, the investors who fund the trials, and the patients who participate-are the lifeblood of the operation.

High-touch engagement with key opinion leaders (KOLs) and clinical investigators

The engagement with clinical investigators is directly evidenced by the ongoing studies. The Phase 2a CRYSTAL-1 study for ORX750, targeting narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), had a total of 55 participants with these conditions who completed dosing in the 2-week crossover cohorts as of the September 23, 2025 data cut-off date. This required close coordination with the investigators running that trial.

Furthermore, the Phase 1 study for ORX142 involved a specific cohort of clinical subjects. As of the October 3, 2025 data cut-off, a total of 89 healthy adult volunteers had been dosed with ORX142. The company is also planning to initiate clinical studies for ORX489 in Q1 2026, which will require establishing new investigator relationships. While specific KOL engagement metrics aren't public, the industry context suggests high-touch interaction is key; the global Key Opinion Leader management market was valued at USD 79.6 billion in 2025.

Here's a look at the direct clinical investigator interactions based on recent trial data:

Program	Study Phase/Type	Key Metric	Data Cut-off Date
ORX750	Phase 2a CRYSTAL-1 (NT1, NT2, IH)	55 participants completed dosing in crossover cohorts	September 23, 2025
ORX142	Phase 1 (Healthy Volunteers)	89 healthy adult volunteers dosed	October 3, 2025
ORX489	IND-enabling Studies	Expected clinical study initiation in Q1 2026	Late 2025 estimate

Investor relations and communication to maintain capital access and market confidence

Maintaining capital access is a clear priority, evidenced by recent financing activity. Centessa Pharmaceuticals plc announced the pricing of an underwritten public offering of American Depositary Shares (ADSs) totaling $250,000,000 on November 11, 2025. This directly supports the capital needs for ongoing development.

Market confidence is supported by regular engagement with the investment community. Members of management were scheduled to participate in multiple investor conferences in late 2025 and early December 2025, including the Guggenheim 2nd Annual Healthcare Innovation Conference and the 37th Annual Piper Sandler Healthcare Conference. As of September 30, 2025, the company held $349.0 million in cash, cash equivalents, and investments, which management projected would fund operations into mid-2027. The stock, trading as CNTA on NASDAQ, had a reported price of $28.47 at one point in November 2025. Analyst sentiment showed an average one-year price target of $35.70/share as of November 17, 2025.

Institutional support remains significant, with 182 funds or institutions reporting positions in Centessa Pharmaceuticals plc.

Direct interaction with regulatory bodies (e.g., FDA) for clinical trial and approval processes

Direct interaction with the U.S. Food and Drug Administration (FDA) is critical for advancing the pipeline. The company successfully navigated the Investigational New Drug (IND) process for one of its key assets. Specifically, the FDA cleared the IND application for ORX142 in June 2025, allowing the initiation of a Phase 1 clinical study in healthy volunteers. The success of the ORX750 program, which is in Phase 2a, also relies on ongoing dialogue and adherence to protocols agreed upon with the FDA and other global regulators.

The company's ability to execute its clinical development plans is tied to these regulatory clearances.

• IND clearance for ORX142 received in June 2025.
• ORX750 Phase 2a study is ongoing, with data readouts expected in 2025.
• ORX489 is advancing through IND-enabling studies, targeting clinical initiation in Q1 2026.

Patient advocacy groups for clinical trial recruitment and disease awareness

Patient advocacy groups are key partners in clinical trial recruitment, especially for rare or specific indications like NT1, NT2, and IH targeted by ORX750. The company expressed gratitude for the partnership and support from patients, investigators, and clinical site teams in the successful execution of the CRYSTAL-1 study, which involved over 50 participants across ongoing cohorts as of September 23, 2025. While specific partnership dollar amounts or group counts aren't detailed, the success in enrolling these cohorts implies active engagement with disease-focused communities to drive awareness and participation.

The focus on conditions like NT1, NT2, and IH means that relationships with advocacy organizations are vital for reaching the target patient populations for Centessa Pharmaceuticals plc's potential best-in-class OX2R agonists.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Channels

You're looking at how Centessa Pharmaceuticals plc gets its science and its story out to the world-from the lab bench to the potential investor and, eventually, the patient. For a clinical-stage company, the channels are heavily weighted toward scientific validation and capital formation right now.

Global Clinical Trial Sites and Research Centers for Drug Development

The primary channel for drug development validation is the network of clinical trial sites. Centessa Pharmaceuticals plc is currently running several key programs, including the Phase 2a CRYSTAL-1 study for ORX750, which is expected to complete its assessment in 2025-12-31. The company also has an ongoing Phase 1 first-in-human study for ORX142.

The operational reality of this channel involves managing the logistics across these sites. Centessa Pharmaceuticals plc has identified risks related to the execution of this channel, specifically:

• Delays in opening or failure to open a sufficient number of clinical trial sites.
• Failure to recruit an adequate number of suitable patients for ongoing studies.
• Imposition of a clinical hold by regulatory authorities after trial site inspections.

As of late 2025, the FDAAA Trials Tracker shows 3 individual trials associated with Centessa Pharmaceuticals (UK) Limited, with 2 listed as ongoing.

Scientific and Medical Conferences for Presenting Phase 2a Data

Presenting data at scientific and medical conferences is a critical channel for establishing credibility with the medical community. Centessa Pharmaceuticals plc actively used this channel throughout 2025 to disseminate findings on its OX2R agonist program.

Key scientific presentation channels in 2025 included:

• Poster Presentation at World Sleep 2025 in Singapore (September 8, 2025).
• Poster Presentations at SLEEP 2025 (June 11, 2025).
• Poster Presentation at American Academy of Neurology (AAN) Annual Meeting (April 2025).

Data readouts for ORX750 in NT1, NT2, and IH were expected in 2025.

Investor Roadshows and Corporate Presentations to Raise Capital

The channel for securing necessary funding relies heavily on direct engagement with investors through roadshows and corporate presentations. Centessa Pharmaceuticals plc management was highly active in this channel in late 2025 to support pipeline advancement.

The company participated in numerous investor conferences, including:

Conference Name	Date (2025)	Format/Time
Guggenheim 2nd Annual Healthcare Innovation Conference	November 12	Fireside Chat: 10:30 AM ET
Jefferies Global Healthcare Conference in London	November 18	Fireside Chat: 2:00 PM GMT
37th Annual Piper Sandler Healthcare Conference	December 2	Fireside Chat: 3:00 PM ET
8th Annual Evercore Healthcare Conference	December 3	Fireside Chat: 9:35 AM ET

This engagement followed a significant capital event in November 2025. Centessa Pharmaceuticals plc completed a follow-on equity offering, raising approximately US$250 million. This was achieved through the sale of more than 11.6 million American Depositary Shares at US$21.50 per share.

Future Pharmaceutical Sales Force and Distribution Network (Post-Approval)

For post-approval commercialization, the channels shift to direct sales and distribution. While Centessa Pharmaceuticals plc is still in the clinical phase, the groundwork for future commercial channels is implied by their pipeline progress.

Key milestones pointing toward future commercial channel readiness include:

• Planning to initiate the registrational program for ORX750 in Q1 2026.
• Planning to initiate patient studies for ORX142 in Q1 2026.
• Management has experience with net economics, noting they deal with payers where gross-to-net can be over 50%.

Specific figures for the planned size of the Centessa Pharmaceuticals plc sales force or the structure of its dedicated distribution network as of late 2025 are not publicly detailed; however, the company is moving aggressively into the hypersomnolence market, which represents a 'completely new commercial domain' for them. Other industry leaders are adopting platforms like Salesforce Life Sciences Cloud to scale engagement across clinical, medical, and commercial data.

Finance: draft 13-week cash view by Friday.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Customer Segments

You're looking at the core groups Centessa Pharmaceuticals plc targets with its pipeline, especially its orexin receptor 2 (OX2R) agonist franchise, which includes ORX750 for sleep-wake disorders.

Patients with chronic sleep-wake disorders: Narcolepsy Type 1, Narcolepsy Type 2, and Idiopathic Hypersomnia.

The addressable patient pool for Centessa Pharmaceuticals plc's lead candidate, ORX750, is substantial, focusing on conditions like Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH).

• Estimated U.S. population with narcolepsy: approximately 1 in every 2,000 people.
• Total estimated U.S. patients: around 200,000 Americans.
• Total estimated worldwide patients: approximately 3 million people.
• A 2018 German study estimated narcolepsy diagnostic prevalence at 17.88 per 100,000 persons.
• In a patient survey, nearly 48% were diagnosed with NT1.

Neurologists and sleep specialists who prescribe novel therapies.

These are the prescribers who will evaluate Centessa Pharmaceuticals plc's data, particularly from the Phase 2a CRYSTAL-1 study for ORX750 across NT1, NT2, and IH indications. Specialists are looking for potential best-in-class OX2R agonists that can restore normative wakefulness.

Metric	Data Point
ORX750 Study Status (as of Q2 2025)	Phase 2a CRYSTAL-1 ongoing across NT1, NT2, and IH
Expected Data Readouts (2025)	Data expected across all three indications (NT1, NT2, IH)
Potential First-in-Class Target	NT2 and IH

Large pharmaceutical companies seeking to license or acquire late-stage assets.

Potential acquirers assess the value of Centessa Pharmaceuticals plc's pipeline, which includes ORX750, ORX142, and the LockBody technology platform. The company's recent financing activity signals a push to advance these assets toward registrational studies.

• Market Capitalization (as of November 14, 2025): $4.08B.
• Stock Price (as of November 14, 2025): $27.61.
• Recent Capital Raise (November 2025): Approximately US$250 million in a follow-on equity offering.
• Cash Position (as of June 30, 2025): $404.1 million.
• Trailing 12-Month Revenue (as of September 30, 2025): $15M.

Institutional investors and venture capital firms funding high-risk, high-reward biotech.

This segment includes the existing base, such as General Atlantic, Vida Ventures, and Janus Henderson Investors from the initial Series A round of $250M in February 2021, and newer participants from the late 2025 equity raise. These investors are betting on the company's ability to execute on its pipeline while managing its current burn rate.

Financial Metric (as of latest report)	Value
Net Loss Q2 2025	$50.3 million
Cash as of March 31, 2025	$424.9 million
Institutional Ownership Percentage (Q1 data)	82.01%
Total Funding Raised (to date)	$250M in 1 round (Series A)

The company expects its cash position as of June 30, 2025, to fund operations into mid-2027.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Cost Structure

You're looking at the core spending that fuels Centessa Pharmaceuticals plc's pipeline progression, which is heavily weighted toward discovery and development. Honestly, for a clinical-stage biotech, the cost structure is almost entirely dictated by the science.

Research & Development (R&D) expenses are definitely the primary cost driver, totaling $41.6 million in Q3 2025. That number is up from $33.9 million in the same quarter last year, showing the ramp-up in clinical activities, especially with the ORX750 Phase 2a study ongoing. This spending funds the clinical trials, lab work, and the people running those complex programs.

You're also dealing with high fixed costs associated with clinical trial execution and manufacturing scale-up. These aren't costs that drop just because you have a slow month; running a trial with 89 volunteers, like the ORX142 Phase 1 study, requires consistent, significant spending on site fees, monitoring, and supply chain setup. It's the nature of the beast in pharma development.

Here's a quick look at the key expense components from the latest reporting period:

Cost Metric	Q3 2025 Amount	Year-to-Date (YTD) 2025 Amount	Prior Year Q3 Comparison (R&D)
Research & Development (R&D) Expenses	$41.6 million	$117.7 million	$33.9 million (Q3 2024)
General & Administrative (G&A) Expenses	$12.2 million	$36.5 million	$12.5 million (Q3 2024)
Net Cash Used in Operations (YTD)	N/A	$(138.0) million	$(99.3) million (YTD 2024)

General and Administrative (G&A) expenses were $12.2 million in Q3 2025. That reflects a lean corporate structure, especially when you compare it to the R&D spend. You see G&A staying relatively flat or even slightly decreasing year-over-year, which is a good sign of cost discipline at the corporate level.

The company anticipates future increases in G&A, which will likely include costs associated with maintaining compliance as a public company, plus fees for outside consultants, lawyers, and accountants. This ties into the need for significant capital expenditure on intellectual property maintenance and licensing fees, though specific IP maintenance dollar amounts aren't broken out separately from general operating costs.

The cost management strategy is clearly focused on extending the runway. As of September 30, 2025, Centessa Pharmaceuticals plc held $349.0 million in cash, cash equivalents, and investments. Management expects this cash position to fund operations into mid-2027 based on current operating plans.

Key cost considerations include:

• The R&D spend is directly tied to advancing the OX2R agonist pipeline.
• The YTD R&D expense of $117.7 million shows the cumulative investment pressure.
• The company reported an annual interest expense of $8.7 million YTD on its term loan.
• The net loss for Q3 2025 was $54.9 million.

Finance: draft 13-week cash view by Friday.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Centessa Pharmaceuticals plc as of late 2025, and honestly, it's a classic biotech story right now: funding the pipeline through non-operating income while waiting for the main event.

Non-product revenue from upfront payments and milestones is the most concrete income stream recognized so far this year. For the six months ended June 30, 2025, Centessa Pharmaceuticals plc reported $15,000 thousand, or $15.0 million, in license and other revenue. This was the upfront payment recognized in Q1 2025 related to the license agreement for its proprietary LockBody platform with Genmab A/S, which was executed on February 14, 2025. This type of revenue is non-recurring and should be modeled as such unless another business development event occurs.

The potential for future non-product revenue is significant, tied directly to the success of partnered programs. The Genmab agreement is a prime example of this structure, which is common for a company at this stage. Here's a quick look at the potential value unlocked by that single deal:

• Option exercise fees potentially totaling up to an additional $15 million.
• Eligibility for potential payouts of approximately $230 million in development, regulatory, and sales milestones per product.
• Tiered royalties ranging in the mid-single digits on annual global net licensed product sales.

To be fair, the company is still entirely dependent on these financing and partnership events because Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. This means there is zero revenue from product sales as of late 2025; the company remains pre-revenue from product sales and continues to report significant net losses and a large accumulated deficit.

Given the high cash burn associated with advancing its pipeline, the primary funding source is equity financing, which has recently been substantial to shore up the balance sheet. Centessa Pharmaceuticals plc completed a significant follow-on public offering in November 2025, raising approximately $250 million. This offering involved American Depositary Shares sold at $21.50 each. This capital injection boosted cash reserves to around $619 million, which management stated provides funding clarity into mid-2027 under current plans. This financing activity is critical to supporting the advancement of the ORX750 program into pivotal clinical trials.

Here's a summary mapping the key financial components that currently constitute Centessa Pharmaceuticals plc's cash inflow strategy:

Revenue/Financing Type	Specific Amount/Range	Recognition/Status
Recognized License Revenue (Q1 2025)	$15.0 million	Recognized upfront payment from Genmab deal
Potential Future Milestones (Genmab)	Up to approx. $230 million per product	Contingent upon development/regulatory/sales success
Recent Equity Financing (Nov 2025)	$250.0 million	Completed follow-on public offering
Total Stated Liquidity (June 30, 2025)	$404.1 million	Cash, cash equivalents, and investments before Nov 2025 raise
Existing Financing Facility	Up to $125.0 million	At-The-Market (ATM) Program capacity

What this estimate hides is that the $250 million raise, while necessary, also means current shareholders have experienced dilution. Finance: draft 13-week cash view by Friday.